These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. [Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?]. Valencia ME; Moreno V; Laguna F; González-Lahoz JM Enferm Infecc Microbiol Clin; 2001 Jan; 19(1):37-9. PubMed ID: 11256251 [No Abstract] [Full Text] [Related]
10. Justifying research risks in a clinical trial for treatment of multidrug-resistant tuberculosis. Heilig CM; Chia D; El-Sadr WM; Hirsch-Moverman Y; Kenzie WR; Saukkonen J; Villarino ME; Padayatchi N IRB; 2011; 33(4):10-7. PubMed ID: 21932482 [No Abstract] [Full Text] [Related]
11. [Linezolid, an agent from a new class of antibiotics]. Slebos DJ; Van Altena R Ned Tijdschr Geneeskd; 2004 Dec; 148(49):2462; author reply 2462-3. PubMed ID: 15626313 [No Abstract] [Full Text] [Related]
12. Optic neuropathy secondary to Linezolid for multidrug-resistant mycobacterial spinal tuberculosis. Agrawal R; Addison P; Saihan Z; Pefkianaki M; Pavesio C Ocul Immunol Inflamm; 2015 Feb; 23(1):90-2. PubMed ID: 24432953 [TBL] [Abstract][Full Text] [Related]
13. Linezolid for multidrug-resistant tuberculosis. Cox H; Ford N; Hughes J; Goemaere E Lancet Infect Dis; 2013 Jan; 13(1):16. PubMed ID: 23257228 [No Abstract] [Full Text] [Related]